Navigation

NICE requests more data on aripiprazole for schizophrenia

In draft guidance, published today (10 September 2010), NICE has asked Bristol-Myers Squibb and Otsuka Pharmaceuticals to provide more data on the effectiveness of their product, aripiprazole (Abilify), as a treatment for schizophrenia in people aged 15 to 17 years.

This draft guidance has been issued for consultation and the manufacturer now has an opportunity to respond to the independent Appraisal Committee's considerations and requests.

NICE has requested further evidence on the clinical and cost effectiveness of aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years compared with each of the atypical antipsychotics routinely used in UK clinical practice (risperidone, olanzapine, quetiapine, amisulpride and clozapine [as rescue therapy]).

Dr Carole Longson, Health Technology Evaluation Centre Director at NICE said: “The independent Appraisal Committee could not assess whether aripiprazole is a cost-effective treatment option because it did not have sufficient information to do so. The next step in the NICE process is for the manufacturer to consider the Committee's comments and respond to its request for further evidence.”

NICE's preliminary recommendations are available for public consultation from 10 September 2010 until 1 October 2010 at http://guidance.nice.org.uk/TA/Wave22/10. Comments received during this consultation will be considered by the Committee at their next meeting and following this the updated draft or final guidance may be issued. Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments.

Notes to Editors

About the guidance

1. View the Schizophrenia - aripiprazole guidance for further information.

About NICE

2. The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.

3. NICE produces guidance in three areas of health:

  • public health - guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector
  • health technologies - guidance on the use of new and existing medicines, treatments and procedures within the NHS
  • clinical practice - guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.

Download PDF version

This page was last updated: 09 September 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.